Lv12
80 积分 2024-08-19 加入
Medication safety in chronic kidney disease
8小时前
已完结
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
13小时前
已完结
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis
1天前
已完结
OA08.01 BMS-986504 in Patients With Homozygous MTAP-Deletion (Del): Clinical Results in Patients With NSCLC Enrolled in CA240-0007
6天前
已关闭
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
14天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
15天前
已完结
PP01.55: RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-Mutant NSCLC
15天前
已关闭
Precision in RNA degradation: helicases, ribosome and RNA polymerase stalling, and RNA modifications
16天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
17天前
已完结
From Undruggable to Degradable: Strategic Expansion of Targeted Protein Degradation in Cancer Therapy
19天前
已完结
皖公网安备34019202002308
